The Safety Record, Distilled

The short version

BPC-157 — body protection compound 157 — is a 15-amino-acid peptide derived from a protein in human gastric juice. It is a research chemical, not an approved medicine. The published preclinical record is unusually quiet: at 2 grams per kilogram in mice, no animal has died and no toxic effects have appeared; the LD50 is undefined. Three small human pilot studies — IV infusion in two adults, injections into knees, and bladder instillation — have reported zero adverse events to date. None of that means it is safe for human use: the human dataset is tiny, large randomized controlled trials have not been completed, and the FDA classifies BPC-157 as an unapproved new drug. What this dossier documents is the preclinical safety record as it stands — and what it does not yet show. For a plain account of reported effects and cautions, see the effects page.

A Compound Whose Lethal Dose Has Never Been Found

The first thing to know about the BPC-157 safety record is that it is, by the standards of preclinical pharmacology, unusually quiet. Researchers have administered the peptide to mice at 2 grams per kilogram — intravenously and by oral gavage — and found zero mortality, zero toxic effects, zero behavioral disturbance. The LD50 — the dose that kills half a test population, the number every compound eventually earns in toxicology — remains undefined for BPC-157 ^[1]. The LD1, the dose that kills one percent of subjects, has also never been achieved. This is not absence of data. It is an affirmative finding.

Body Protection Compound 157 is a 15-amino-acid sequence — GEPPPGKPADDAGLV in the single-letter notation — derived from a protein native to human gastric juice. Its molecular weight is 1419.5 Da. The 'stable' prefix in its formal name refers to a measured fact: the peptide is resistant to degradation in gastric acid for more than 24 hours, an unusual property that underlies its oral activity across dozens of experimental models ^[2]. When it is metabolized, it breaks primarily into proline and the other standard amino acids in its sequence, which re-enter normal amino acid metabolic pathways without accumulation ^[13].

This origin story matters for the safety argument. A peptide that the body's gastric mucosa produces natively, that metabolizes into constituent amino acids without exotic intermediaries, and that has never killed a rodent at any tested dose is a different kind of molecule than a synthetic small-molecule compound. That is not a claim of safety for human use — the regulatory position is unambiguous, and it is addressed on every page of this dossier. It is an observation about the nature of the evidence.

What follows in this volume is an editorial reading of that evidence: the NOAEL data from rats and dogs, the genotoxicity and teratogenicity evaluations, the pharmacokinetic profile, the three small human pilot studies published as of 2025, and the regulatory and WADA context that frames any real-world consideration of the compound.

What the Preclinical Record Shows

The toxicology dossier for BPC-157 spans multiple species and multiple protocols. In a 28-day repeated-dose study in Sprague-Dawley rats, daily intramuscular doses of 0.2, 1, and 4 mg/kg/day produced no apparent adverse changes compared to vehicle controls across any of the three dose levels ^[2]. No gross pathology. No organ weight changes. No clinical chemistry abnormalities attributable to the peptide. The NOAEL — the No Observed Adverse Effect Level, the standard preclinical safety benchmark — was established at or above 4 mg/kg/day in rats.

In beagle dogs, a 28-day intramuscular repeated-dose study at 10 mg/kg showed no distinct adverse effects ^[2]. A transient decrease in creatinine was observed at 2 mg/kg in a separate dog protocol, but it resolved spontaneously after a two-week washout period and produced no irreversible organ changes ^[2]. The single-dose intramuscular protocol at 20 mg/kg in rats produced no deaths, no abnormalities in body weight, food intake, or behavior — at a dose more than 2,000 times the typical preclinical therapeutic range ^[2].

The standard genotoxicity battery — Ames test for mutagenicity, chromosomal aberration assay — showed no genotoxic effects ^[5]. Embryo-fetal toxicity and teratogenicity evaluations in mice, rats, rabbits, and dogs found no teratogenic effects and no adverse developmental findings ^[5]. Anaphylaxis and local injection-site toxicity assays returned negative ^[5]. The comprehensive preclinical safety package, across four species and both single- and repeated-dose protocols, produced no finding that would constitute a safety signal under standard toxicological criteria ^[5][2].

The mechanistic argument for this profile rests in part on the peptide's endogenous origin and rapid metabolism. BPC-157 does not accumulate. Its elimination half-life is under 30 minutes in both rats and beagle dogs following intramuscular administration ^[13]. In a human pilot study, plasma concentrations returned to baseline within 24 hours ^[6].

Three Human Pilot Studies, Zero Adverse Events

As of 2025, three small human pilot datasets have been published. The most recent — and the most methodologically ambitious — administered BPC-157 by intravenous infusion to two healthy adult volunteers: 10 mg on day one, 20 mg on day two ^[6]. Monitoring throughout included comprehensive metabolic panel, thyroid function tests, ECG, vital signs, and plasma concentration tracking. No adverse events were documented. No clinically meaningful changes were observed in hepatic enzymes, renal function markers, thyroid values, or cardiac parameters. Plasma concentrations cleared to baseline within 24 hours ^[6].

The second dataset is a retrospective review of 17 patients who received intra-articular BPC-157 injections for multiple types of chronic knee pain ^[14]. Fourteen of 16 evaluable patients — 87.5% — reported significant pain improvement at 6 to 12 months. No adverse events were documented across the cohort ^[14]. The third dataset, a bladder instillation study for interstitial cystitis, similarly reported no adverse effects ^[21].

These are small studies. They are not randomized. They are not placebo-controlled. The authors of every systematic review and narrative review of this literature are explicit about these limitations ^[16][21]. The signal from the human data, however, is consistent with the preclinical safety profile: no adverse events in any of the three published human datasets, short plasma half-life, no accumulation, no organ-marker changes. The limitation is not what the existing data shows — it is how little of it there is.

The regulatory conclusion follows directly from that limitation. BPC-157 is not approved by the FDA for any human indication as of 2025. It is classified as an unapproved new drug. It is prohibited under WADA's S0 Non-Approved Substances category — a category that carries sanctions regardless of whether any adverse event is documented. This dossier records what the research shows; it does not minimize what the regulatory record means.

The Scope of This Dossier

This site is an independent editorial project. The pages that follow are organized as a reading companion to the published literature:

The research page covers BPC-157's mechanism — the VEGFR2-Akt-eNOS signaling axis, the NO system modulation, the organ-protective effects in liver, kidney, tendon, and nervous system — alongside the key preclinical safety findings presented as a ledger of species, route, dose, and outcome.

The dosage page documents what was actually studied in preclinical protocols: the µg/kg and ng/kg intraperitoneal doses in rodents, the mg/kg intramuscular doses in dogs, the oral drinking-water concentrations, the human IV pilot doses. All of this is research-context-only information — the framing throughout is 'studied at X in species Y by route Z,' never prescriptive.

The FAQ addresses the questions researchers and readers most commonly bring to the published literature: what the NOAEL means, what it does not mean, why the LD50 remains undefined, what the human data does and does not establish, and what WADA's S0 classification entails.

The references page carries the full citation list with DOIs and PubMed URLs — the provenance behind every claim in this volume.